![](/ServeContent?url=http%3A%2F%2Farchfami.ama-assn.org%2Ficons%2Fspacer.gif)
Tissue-type Plasminogen Activator (tPA) or Low-Molecular-Weight Heparin for Acute Ischemic Stroke
Arch Fam Med. 1999;8:263.
As compared with placebo, patients treated with tPA were at least 30% more likely to have minimal or no disability at 3 months on the assessment scales. There was a higher likelihood of intracerebral hemorrhage in the tPA group. (N Engl J Med. 1995;333:1581-1587.)
|